Response to Comments: Thyroid Nodule Molecular Testing

This document records that National Government Services solicited public and provider comments on the Thyroid Nodule Molecular Testing LCD. The notice period began October 14, 2021, with the final determination effective December 1, 2021; no clinical coverage criteria, exclusions, or claim documentation requirements are specified in this notice.

"National Government Services solicits comments from the provider community and from members of the public as part of LCD development for Thyroid Nodule Molecular Testing."

Sign up to see full coverage criteria, indications, and limitations.